Summary
The effects of two oxprenolol oral osmotic (OROS) delivery systems on heart rate and blood pressure before and during recovery from exercise at a predetermined load were examined in twelve patients with hypertension previously responding to beta-blocker monotherapy. Haemodynamic responses were attenuated during the 24 h after single and repeated (15 days') once daily administrations of 10/170 and 16/260 oxprenolol OROS.
At 24 h after repeated doses, compared to placebo there were significant reductions in resting blood pressure and in heart rate immediately following exercise. Attenuation of heart rate after exercise was dose related but differences between the systems with respect to resting heart rate and blood pressure were inconsistent. Antihypertensive responses after repeated doses were greater than those after single doses.
However, reductions in resting and exercise heart rates were consistently less on chronic therapy. This may reflect enhanced expression of the partial agonist activity of oxprenolol due to altered receptor sensitivity after prolonged beta-blockade.
The plasma oxprenolol profiles after both systems indicated slow absorption and substantial concentrations were apparent 24 h after drug administration.
These observations suggest that both oxprenolol OROS systems display sustained drug release and on once daily dosing provide 24 h beta-blockade and control of blood pressure at rest and following exercise.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aarons RD, Nices AS, Gal J, Hegstrand LR, Molinoff PB (1980) Elevation of β-adrenergic receptor density in human lymphocytes after propranolol administration. J Clin Invest 65: 949–957
Apt K (1987) Descriptive data analysis: Conflict between confirmatory and exploratory data analysis. Meth Inform Med 26: 77–88
Barritt DW, Marshall AJ (1977) Beta-blockade in essential hypertension: An analysis of response to oxprenolol. Br Heart J 39: 825–828
Bennett PN, Bennett J, Bradbrook I, Francis J, John VA, Rogers M, Turner P, Warrington SJ (1985) Single-dose pharmacokinetic and pharmacodynamic comparison of polymer-matrix (Slow Trasicor) and OROS dosage forms of oxprenolol in healthy volunteers. Br J Clin Pharmacol 19: 171S-175S
Bolli P, Bühler FR, Raeder EA, Amann FW, Meier M, Rogg H, Burzhardt D (1981) Lack of β-adrenoceptor hypersensitivity after abrupt withdrawal of long-term therapy with oxprenolol. Circulation 64: 1130–1134
Breckenridge A (1983) Which beta-blocker? Br Med J 286: 1085–1088
Degen PH, Riess W (1976) Simplified method for the determination of oxprenolol and other β-receptor blocking agents in biological fluids by gas-liquid chromatography. J Chromatogr 121: 72–75
Israili ZH (1979) Correlation of pharmacological effects with plasma levels of antihypertensive drugs in man. Annu Rev Pharmacol Toxicol 19: 25–52
Leahey WJ, Neill JD, Varma MPS, Shanks RG (1980) Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol. Eur J Clin Pharmacol 17: 419–424
Leenen FHH, Coenen CHM, Zanderland M, Maas AHJ (1980) Effects of cardioselective and nonselective β-blockade on dynamic exercise performance in mildly hypertensive men. Clin Pharmacol Ther 28: 12–21
McDevitt DG, Brown HC, Carruthers SG, Shanks RG (1977) Influence of intrinsic sympathomimetic activity and cardioselectivity on beta-adrenoceptor blockade. Clin Pharmacol Ther 21: 556–566
Mason WD, Winer N (1976) Pharmacokinetics of oxprenolol in normal subjects. Clin Pharmacol Ther 20: 401–412
Materson BJ, Michael UF, Oster JR, Perez-Stable EC (1976) Antihypertensive effects of oxprenolol and propranolol. Clin Pharmacol Ther 20: 142–151
Petrie JC, Jeffers TA, Robb OJ, Scott AK, Webster J (1980) Atenolol, sustained-release oxprenolol and long-acting propranolol in hypertension. Br Med J 280: 1573–1575
Racine-Poon A, Moppert J (1985) Concentration-effect relationship of oxprenolol in healthy volunteers: A retrospective analysis. Br J Clin Pharmacol 19: 143S-149S
Robinson BF, Epstein SE, Beiser GD, Braunwald E (1966) Control of the heart rate by the autonomic nervous system: Studies in man on the interrelation between baro-receptor mechanisms and exercise. Circ Res 19: 400–411
Rosendorff C, Susanni E, Hurwitz ML, Ross FP (1985) Adrenergic receptors in hypertension: Radioligand binding studies. J Hypertens 3: 571–581
Serlin MJ, Orme MLE, MacIver M, Green GJ, Sibeon RG, Breckenridge AM (1983) The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension. Br J Clin Pharmacol 15: 519–527
Shanks RG (1976) The properties of beta-adrenoceptor antagonists. Postgrad Med J 52 [Suppl 4]: 14–20
Thadani U (1983) Beta-blockers in hypertension. Am J Cardiol 52: 10D-15D
Theeuwes F, Swanson DR, Guittard G, Ayer A, Khanna S (1985) Osmotic delivery systems for the β-adrenoceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once-daily administration. Br J Clin Pharmacol 19: 69S-76S
Tuomilehto J, Nissinen A (1979) Double-blind comparison of metoprolol, alprenolol and oxprenolol in hypertension. Eur J Clin Pharmacol 16: 369–374
Winer BJ (1971) Statistical principles in experimental design. McGraw-Hill, New York
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McInnes, G.T., Brodie, M.J. Evaluation of two oxprenolol oral osmotic (OROS) delivery systems in patients with essential hypertension. Eur J Clin Pharmacol 34, 605–611 (1988). https://doi.org/10.1007/BF00615225
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00615225